(NASDAQ: NKTX) Nkarta's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Nkarta's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NKTX's revenue for 2026 to be $10,570,143,000, with the lowest NKTX revenue forecast at $10,570,143,000, and the highest NKTX revenue forecast at $10,570,143,000. On average, 2 Wall Street analysts forecast NKTX's revenue for 2027 to be $2,512,170,653, with the lowest NKTX revenue forecast at $584,881,246, and the highest NKTX revenue forecast at $4,439,460,060.
In 2028, NKTX is forecast to generate $8,040,144,039 in revenue, with the lowest revenue forecast at $777,962,525 and the highest revenue forecast at $15,908,065,215.